{"artifact":{"id":"open_question-282550ae-fc58-4729-8c1d-45b72c153918","artifact_type":"open_question","entity_ids":"[\"researchers\"]","title":"What trial designs can most efficiently translate mechanistic findings in Neuropsychiatric Disorders and Alzheimer Disease into clinically meaningful interventions?","quality_score":0.5,"created_by":"backfill_open_questions","provenance_chain":"[]","content_hash":"1fd01839adf3f1de57f8a268b6423bdec04aad577fa5921e5e947cfa42e8a6a3","metadata":{"status":"open","_origin":{"url":null,"type":"internal","tracked_at":"2026-04-26T03:29:29.730938"},"field_tag":"researchers","source_id":"researchers-thomas-sudhof","sub_field":"thomas-sudhof","source_kind":"wiki","question_hash":"23b24798b7b5d3d7a70d6c5d82968410d850203b744893a21015c7523d5788e8","question_text":"What trial designs can most efficiently translate mechanistic findings in Neuropsychiatric Disorders and Alzheimer Disease into clinically meaningful interventions?","importance_elo":1500,"_schema_version":1,"evidence_summary":"Extracted from wiki page researchers-thomas-sudhof","evidence_xref_at":"2026-04-27T14:25:05.375824+00:00","tractability_score":0.5,"potential_impact_score":0.5},"created_at":"2026-04-25T20:29:29.731056-07:00","updated_at":"2026-04-25T20:29:29.731056-07:00","version_number":4,"parent_version_id":null,"version_tag":null,"changelog":null,"is_latest":1,"lifecycle_state":"active","superseded_by":null,"deprecated_at":null,"deprecated_reason":null,"dependencies":null,"market_price":0.5,"origin_type":"internal","origin_url":null,"lifecycle_changed_at":"2026-04-25T20:29:29.731056-07:00","citation_count":0,"embed_count":0,"derivation_count":0,"support_count":0,"contradiction_count":0,"total_usage":0.0,"usage_score":0.5,"usage_computed_at":null,"quality_status":null,"contributors":[],"answers_question_ids":null,"deprecated_reason_detail":null,"deprecated_reason_code":null,"commit_sha":null,"commit_submodule":null,"last_mutated_at":"2026-05-16T14:51:34.657673-07:00","disputed_at":null,"gap_id":null,"mission_id":null,"intrinsic_priority":null,"effective_priority":null,"artifact_id":"ddaa43aa-4825-4846-8126-66c20c47a18a","artifact_dir":null,"primary_filename":null,"accessory_filenames":null,"folder_layout_version":1,"migrated_to_folder_at":null,"hypothesis_id":null,"authorship":{"kind":"human","contributors":[{"role":"author","actor_ref":"backfill_open_questions"}]},"epistemic_tier":"T3_provisional","created_by_agent_id":null},"outgoing_links":[{"target_artifact_id":"wiki-researchers-thomas-sudhof","link_type":"derives_from","strength":0.9,"evidence":"{\"method\": \"open_question_wiki_crosslink\", \"cycle\": \"artifact-enrichment-2026-04-27\"}"},{"target_artifact_id":"experiment-exp-wiki-experiments-n-of-1-clinical-trial-cbs-psp","link_type":"partial_answer_for","strength":0.78,"evidence":"{\"confidence\": 0.78, \"judge_persona\": \"domain-expert\", \"model\": \"all-MiniLM-L6-v2\"}"},{"target_artifact_id":"experiment-exp-wiki-experiments-biomarker-guided-therapy-sequencing-ad","link_type":"partial_answer_for","strength":0.75,"evidence":"{\"confidence\": 0.75, \"judge_persona\": \"domain-expert\", \"model\": \"all-MiniLM-L6-v2\"}"},{"target_artifact_id":"experiment-exp-wiki-experiments-anti-tau-immunotherapy-dosing","link_type":"partial_answer_for","strength":0.68,"evidence":"{\"confidence\": 0.68, \"judge_persona\": \"domain-expert\", \"model\": \"all-MiniLM-L6-v2\"}"},{"target_artifact_id":"experiment-exp-b7e92df4-68ed-4205-bbf6-875572bec993","link_type":"partial_answer_for","strength":0.62,"evidence":"{\"confidence\": 0.62, \"judge_persona\": \"domain-expert\", \"model\": \"all-MiniLM-L6-v2\"}"}],"incoming_links":[],"current_artifact_id":"open_question-282550ae-fc58-4729-8c1d-45b72c153918","is_canonical":true,"supersede_chain":["open_question-282550ae-fc58-4729-8c1d-45b72c153918"]}